Vanguard Personalized Indexing Management LLC Decreases Stock Holdings in uniQure N.V. $QURE

Vanguard Personalized Indexing Management LLC trimmed its holdings in shares of uniQure N.V. (NASDAQ:QURE) by 6.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,751 shares of the biotechnology company’s stock after selling 895 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in uniQure were worth $178,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new position in shares of uniQure in the second quarter worth $117,000. Mraz Amerine & Associates Inc. bought a new position in shares of uniQure in the first quarter worth $106,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of uniQure by 3.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 279,999 shares of the biotechnology company’s stock worth $2,968,000 after acquiring an additional 10,019 shares during the period. OMERS ADMINISTRATION Corp bought a new position in shares of uniQure in the first quarter worth $152,000. Finally, Diamond Hill Capital Management Inc. boosted its holdings in shares of uniQure by 22.8% in the first quarter. Diamond Hill Capital Management Inc. now owns 82,653 shares of the biotechnology company’s stock worth $876,000 after acquiring an additional 15,333 shares during the period. 78.83% of the stock is owned by institutional investors.

Insider Transactions at uniQure

In related news, CFO Christian Klemt sold 15,000 shares of the business’s stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the transaction, the chief financial officer owned 217,730 shares in the company, valued at $11,975,150. The trade was a 6.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew C. Kapusta sold 226,316 shares of the business’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the transaction, the chief executive officer owned 651,454 shares in the company, valued at approximately $27,009,282.84. This represents a 25.78% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 244,316 shares of company stock worth $10,328,181. 4.79% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on QURE shares. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. The Goldman Sachs Group lifted their price objective on uniQure from $13.00 to $56.00 and gave the company a “neutral” rating in a research note on Thursday, September 25th. UBS Group set a $95.00 target price on uniQure in a research report on Thursday, September 25th. Wells Fargo & Company upped their target price on uniQure from $65.00 to $80.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Finally, Guggenheim upped their target price on uniQure from $28.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average target price of $71.75.

uniQure Trading Up 2.8%

NASDAQ QURE opened at $61.01 on Friday. uniQure N.V. has a 1-year low of $5.35 and a 1-year high of $65.14. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The stock has a 50-day moving average of $35.42 and a 200-day moving average of $21.47. The firm has a market cap of $3.35 billion, a PE ratio of -15.56 and a beta of 0.56.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The company had revenue of $5.26 million during the quarter, compared to analyst estimates of $5.00 million. As a group, sell-side analysts forecast that uniQure N.V. will post -3.75 EPS for the current year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.